Physician profile
Ayodele E Adeigbola
NPI 1407900053
$2,675.25
in general payments reported to CMS, 2019-2025
19 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $307 · 2021: $120 · 2022: $75.09 · 2023: $394 · 2024: $371 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $711.07 | 2021-2025 | Vraylar |
| Allergan, INC. | $481.32 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $323.56 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $281.13 | 2024-2025 | Rexulti |
| Lundbeck LLC | $214.98 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $154.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $73.25 | 2019-2020 | |
| Neos Therapeutics, LP | $66.49 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $53.10 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $52.46 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 | |
| Eisai INC. | $46.38 | 2021 | |
| Sunovion Pharmaceuticals INC. | $32.45 | 2019 | |
| Arbor Pharmaceuticals, INC. | $32.33 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $24.73 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $21.98 | 2019 | |
| Adlon Therapeutics L.P. | $20.01 | 2019 | |
| Tris Pharma INC | $19.55 | 2019 | |
| Alfasigma USA, INC. | $19.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayodele Adeigbola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.